Please assess the completion status of the following clinical trial:

Trial Title: ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No fever on day of vaccination~* Females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal~* Underlying chronic illness must be stable~Exclusion Criteria:~* History of hypersensitivity reaction to any vaccine component~* Prior history of herpes zoster~* Prior receipt of varicella or zoster vaccine~* Pregnant or breastfeeding~* Have recently received immunoglobulins or blood products other than autologous blood transfusion~* Received any inactivated other live virus vaccine within 4 weeks prior to vaccination, or is expected to received any other live virus vaccine during the duration of the study~* Received any inactivated vaccine within 7 days prior to vaccination, or is expected to receive any inactivated vaccine during the duration of the study~* Use of immunosuppressive therapy~* Known or suspected immune dysfunction~* Use of nontopical antiviral therapy with activity against herpes virus~* Known or suspected active untreated tuberculosis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zoster Vaccine Live (Type: EXPERIMENTAL): Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).